Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (281-290 of 339) with videos related to

Pageof 34
Sort By:
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
Leukemia Research|April 30, 2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic studyFriederike Braulke, Klaus Jung, Julie Schanz, et al.
American Journal of Hematology|March 16, 2021
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5qVictoria Panagiota, Manja Meggendorfer, Anne Sophie Kubasch, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
Experimental Hematology|April 16, 2016
GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndromeLacramioara Botezatu, Lars C Michel, Hideki Makishima, et al.
Haematologica|October 26, 2014
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Uwe Platzbecker, Catharina Müller-Thomas, et al.
Oncotarget|November 2, 2017
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditionsPeter Valent, Attilio Orazi, David P Steensma, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 34

Showing results (281-290 of 339) with videos related to

Sort By:
Pageof 34
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
Leukemia Research|April 30, 2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic studyFriederike Braulke, Klaus Jung, Julie Schanz, et al.
American Journal of Hematology|March 16, 2021
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5qVictoria Panagiota, Manja Meggendorfer, Anne Sophie Kubasch, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
Experimental Hematology|April 16, 2016
GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndromeLacramioara Botezatu, Lars C Michel, Hideki Makishima, et al.
Haematologica|October 26, 2014
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Uwe Platzbecker, Catharina Müller-Thomas, et al.
Oncotarget|November 2, 2017
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditionsPeter Valent, Attilio Orazi, David P Steensma, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 34